
CYP3A5 Polymorphism in Circulating Tumor Cells Confers an Increased Disease-Free Survival in DLBCL Patients Treated with ...
Introduction Diffuse Large B-Cell Lymphoma (DLBCL) is the most common aggressive type of Non-Hodgkin Lymphoma (NHL) in Mexico and worldwide.1–3 The presence of Circulating Tumor Cells (CTCs) in peripheral blood, which derive from primary tumors, has been …